CWM
PCRX icon

Calamos Wealth Management’s Pacira BioSciences PCRX Stock Holding History

Calamos Wealth Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-4,725
Closed -$227K – 215
2013
Q3 		$227K Buy
+4,725
New +$172K 0.07% 181

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Calamos Wealth Management's PCRX Position: Q4 2013 in Review

Calamos Wealth Management sold out of Pacira BioSciences (PCRX) in Q4 2013, closing a stake of 4,725 shares — an estimated $227K sold.

Calamos Wealth Management first reported a position in PCRX in Q3 2013 and held it in 1 quarter. The position peaked at $227K in Q3 2013. 132 funds tracked by Wall St. Rank hold PCRX as of Q4 2013.

  • Calamos Wealth Management reported no remaining Pacira BioSciences position as of Q4 2013 after selling out during the quarter.
  • Calamos Wealth Management sold 4,725 Pacira BioSciences shares in Q4 2013, an estimated $227K.
  • Calamos Wealth Management first reported a position in Pacira BioSciences in Q3 2013 and held it in 1 quarter.
  • Calamos Wealth Management's Pacira BioSciences position peaked at $227K in Q3 2013.
  • 132 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2013.

Based on Calamos Wealth Management's 13F filing for Q4 2013, filed 14 Feb 2014.